Immunome, Inc. (NASDAQ:IMNM) CEO Buys $999,459.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall purchased 137,100 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $7.29 per share, with a total value of $999,459.00. Following the acquisition, the chief executive officer now directly owns 806,736 shares in the company, valued at $5,881,105.44. This trade represents a 20.47 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Immunome Stock Performance

Shares of IMNM stock traded up $0.14 during trading hours on Wednesday, hitting $7.09. 1,969,061 shares of the company were exchanged, compared to its average volume of 836,155. Immunome, Inc. has a one year low of $6.94 and a one year high of $26.70. The business’s 50-day simple moving average is $9.67 and its two-hundred day simple moving average is $11.44. The stock has a market capitalization of $616.48 million, a price-to-earnings ratio of -0.87 and a beta of 1.93.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The company had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. As a group, analysts anticipate that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on IMNM. Stephens reaffirmed an “overweight” rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Guggenheim cut their target price on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.50.

Institutional Trading of Immunome

A number of large investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Immunome in the 4th quarter worth about $70,000. KLP Kapitalforvaltning AS bought a new stake in shares of Immunome during the 4th quarter worth $75,000. AlphaQuest LLC lifted its stake in Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock valued at $84,000 after buying an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Immunome by 482.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after acquiring an additional 7,129 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in shares of Immunome during the fourth quarter valued at $95,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.